Reforgene listed among China's 2025 biopharma frontrunners
Recently, the 2025 China Biopharmaceutical Front-Runners 100 list was grandly released at the Shanghai Biomedical Investment and Financing Summit and Fudan Biomedical Innovation Development Forum. With its strong technological innovation capability, notable clinical progress of new drugs and excellent corporate growth, Reforgene was successfully selected into the "2025 China Biopharmaceutical Front-Runners 100 list", highlighting its benchmark position in the gene editing drug development field.
The solicitation and release of the Front-Runners list is an important measure to grasp forward-looking hotspots, explore scientific frontiers and build a "wind vane" for industry development. Since 2023, it has been held for three editions, selecting a group of benchmark enterprises across three fields: biomedicine, medical devices and digital health, attracting widespread social attention and discussion. Reforgene feels deeply that its selection into the 2025 China Biopharmaceutical Front-Runners 100 list is the industry's recognition of the company's technological breakthroughs in gene editing and its development path focused on clinical needs, and it further strengthens its original aspiration of "providing curative medicines for patients". In the future, it will continue to deepen its technology, improve drug accessibility, lead the industry with responsibility, help China's biomedicine advance toward a global source of innovation, and let innovative achievements benefit more patients.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.